sybr green master mix Search Results


chamq sybr qpcr master mix  (Vazyme Biotech Co)
99
Vazyme Biotech Co chamq sybr qpcr master mix
Chamq Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chamq sybr qpcr master mix/product/Vazyme Biotech Co
Average 99 stars, based on 1 article reviews
chamq sybr qpcr master mix - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
sybr green real time pcr master mix  (Toyobo)
96
Toyobo sybr green real time pcr master mix
Sybr Green Real Time Pcr Master Mix, supplied by Toyobo, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sybr green real time pcr master mix/product/Toyobo
Average 96 stars, based on 1 article reviews
sybr green real time pcr master mix - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
qpcr sybr green master mix  (Yeasen Biotechnology)
86
Yeasen Biotechnology qpcr sybr green master mix
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Qpcr Sybr Green Master Mix, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qpcr sybr green master mix/product/Yeasen Biotechnology
Average 86 stars, based on 1 article reviews
qpcr sybr green master mix - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier
chamqtm sybr qpcr master mix  (Vazyme Biotech Co)
99
Vazyme Biotech Co chamqtm sybr qpcr master mix
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Chamqtm Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chamqtm sybr qpcr master mix/product/Vazyme Biotech Co
Average 99 stars, based on 1 article reviews
chamqtm sybr qpcr master mix - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
chamq universal sybr qpcr master mix  (Vazyme Biotech Co)
99
Vazyme Biotech Co chamq universal sybr qpcr master mix
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Chamq Universal Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chamq universal sybr qpcr master mix/product/Vazyme Biotech Co
Average 99 stars, based on 1 article reviews
chamq universal sybr qpcr master mix - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
taq pro universal sybr qpcr master mix  (Vazyme Biotech Co)
99
Vazyme Biotech Co taq pro universal sybr qpcr master mix
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Taq Pro Universal Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/taq pro universal sybr qpcr master mix/product/Vazyme Biotech Co
Average 99 stars, based on 1 article reviews
taq pro universal sybr qpcr master mix - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
aceq qpcr sybr green master mix kit  (Vazyme Biotech Co)
94
Vazyme Biotech Co aceq qpcr sybr green master mix kit
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Aceq Qpcr Sybr Green Master Mix Kit, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aceq qpcr sybr green master mix kit/product/Vazyme Biotech Co
Average 94 stars, based on 1 article reviews
aceq qpcr sybr green master mix kit - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
mirna universal sybr qpcr master mix  (Vazyme Biotech Co)
99
Vazyme Biotech Co mirna universal sybr qpcr master mix
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Mirna Universal Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mirna universal sybr qpcr master mix/product/Vazyme Biotech Co
Average 99 stars, based on 1 article reviews
mirna universal sybr qpcr master mix - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
sybrgreen supermix  (Bio-Rad)
99
Bio-Rad sybrgreen supermix
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Sybrgreen Supermix, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sybrgreen supermix/product/Bio-Rad
Average 99 stars, based on 1 article reviews
sybrgreen supermix - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
sybr green method  (Vazyme Biotech Co)
98
Vazyme Biotech Co sybr green method
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Sybr Green Method, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sybr green method/product/Vazyme Biotech Co
Average 98 stars, based on 1 article reviews
sybr green method - by Bioz Stars, 2026-02
98/100 stars
  Buy from Supplier
china r223 01 chamq sybr color qpcr master mix vazyme  (Vazyme Biotech Co)
95
Vazyme Biotech Co china r223 01 chamq sybr color qpcr master mix vazyme
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
China R223 01 Chamq Sybr Color Qpcr Master Mix Vazyme, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/china r223 01 chamq sybr color qpcr master mix vazyme/product/Vazyme Biotech Co
Average 95 stars, based on 1 article reviews
china r223 01 chamq sybr color qpcr master mix vazyme - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
qpcr  (Vazyme Biotech Co)
99
Vazyme Biotech Co qpcr
IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) <t>RT-qPCR</t> assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.
Qpcr, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qpcr/product/Vazyme Biotech Co
Average 99 stars, based on 1 article reviews
qpcr - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

Image Search Results


IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) RT-qPCR assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.

Journal: Frontiers in Oncology

Article Title: Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins

doi: 10.3389/fonc.2022.885656

Figure Lengend Snippet: IFN-γ treatment enhances epithelial-mesenchymal transition (EMT) and metastasis in various tumors. (A) Transwell assays to detect the migration and invasion abilities of different cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assays to examine the effect of IFN-γ treatment (50 ng/ml, 48 h) on expression of EMT markers at the protein level. (C) RT-qPCR assays to detect the changes in expression of EMT markers at the mRNA level after IFN-γ treatment (50 ng/ml, 48 h). Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ****P < 0.0001.

Article Snippet: QRT-PCR was performed using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China).

Techniques: Migration, Western Blot, Expressing, Quantitative RT-PCR, Standard Deviation

IFN-γ treatment promotes MDK expression in different cancers. (A) RT-qPCR assays to detect the expression of MDK in five cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assay to determine the influence of IFN-γ treatment (50 ng/ml, 48 h) on MDK protein levels in five cancer cell lines. Data are shown as the mean ± standard deviation (SD). **P < 0.01, ***P < 0.001, ****P < 0.0001.

Journal: Frontiers in Oncology

Article Title: Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins

doi: 10.3389/fonc.2022.885656

Figure Lengend Snippet: IFN-γ treatment promotes MDK expression in different cancers. (A) RT-qPCR assays to detect the expression of MDK in five cancer cell lines without and with IFN-γ treatment (50 ng/ml, 48 h). (B) Western blotting assay to determine the influence of IFN-γ treatment (50 ng/ml, 48 h) on MDK protein levels in five cancer cell lines. Data are shown as the mean ± standard deviation (SD). **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: QRT-PCR was performed using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Standard Deviation

Dose- and time-dependent effects of IFN-γ on MDK induction. (A) RT-qPCR assays to examine the effect of IFN-γ concentration on MDK induction in the HCT116 cell line. (B) Western blotting assays to examine the effect of IFN-γ concentration on MDK induction in the HCT116 cell line. (C) RT-qPCR assays to examine the effect of IFN-γ treatment time on MDK induction in the HCT116 cell line. (D) Western blotting assays to examine the effect of IFN-γ treatment time on MDK induction and EMT activation in the HCT116 cell line. (E) RT-qPCR assays showing the effect of IFN-γ treatment time on EMT markers in the HCT116 cell line. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, not significant.

Journal: Frontiers in Oncology

Article Title: Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins

doi: 10.3389/fonc.2022.885656

Figure Lengend Snippet: Dose- and time-dependent effects of IFN-γ on MDK induction. (A) RT-qPCR assays to examine the effect of IFN-γ concentration on MDK induction in the HCT116 cell line. (B) Western blotting assays to examine the effect of IFN-γ concentration on MDK induction in the HCT116 cell line. (C) RT-qPCR assays to examine the effect of IFN-γ treatment time on MDK induction in the HCT116 cell line. (D) Western blotting assays to examine the effect of IFN-γ treatment time on MDK induction and EMT activation in the HCT116 cell line. (E) RT-qPCR assays showing the effect of IFN-γ treatment time on EMT markers in the HCT116 cell line. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, not significant.

Article Snippet: QRT-PCR was performed using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China).

Techniques: Quantitative RT-PCR, Concentration Assay, Western Blot, Activation Assay

IFN-γ activates MDK via STAT1. (A) Correlation analyses using the GEPIA 2 online tool ( http://gepia2.cancer-pku.cn/#correlation ) to shown the correlation relationship between STAT1 and MDK using the RNA-seq data of different cancers from the Cancer Genome Atlas (TCGA) database. KIRC, kidney renal clear cell carcinoma; LUSC, Lung squamous cell carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; BRCA, breast invasive carcinoma; COAD, colorectal adenocarcinoma. (B) RT-qPCR and Western blotting assays to detect the effect of IFN-γ treatment (50 ng/ml, 48h) on levels of STAT1 and phosphorylated STAT1 (p-STAT1) in five cancer cell lines. (C) RT-qPCR assays to the effect of STAT1 inhibitor on mRNA levels of STAT1 and MDK in five cancer cell lines. (D) Western blotting assays to examine the effect of STAT1 inhibitor on protein levels of STAT1, p-STAT1 and MDK in five cancer cell lines. Data are shown as the mean ± standard deviation (SD). **P < 0.01, ***P < 0.001, ****P < 0.0001.

Journal: Frontiers in Oncology

Article Title: Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins

doi: 10.3389/fonc.2022.885656

Figure Lengend Snippet: IFN-γ activates MDK via STAT1. (A) Correlation analyses using the GEPIA 2 online tool ( http://gepia2.cancer-pku.cn/#correlation ) to shown the correlation relationship between STAT1 and MDK using the RNA-seq data of different cancers from the Cancer Genome Atlas (TCGA) database. KIRC, kidney renal clear cell carcinoma; LUSC, Lung squamous cell carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; BRCA, breast invasive carcinoma; COAD, colorectal adenocarcinoma. (B) RT-qPCR and Western blotting assays to detect the effect of IFN-γ treatment (50 ng/ml, 48h) on levels of STAT1 and phosphorylated STAT1 (p-STAT1) in five cancer cell lines. (C) RT-qPCR assays to the effect of STAT1 inhibitor on mRNA levels of STAT1 and MDK in five cancer cell lines. (D) Western blotting assays to examine the effect of STAT1 inhibitor on protein levels of STAT1, p-STAT1 and MDK in five cancer cell lines. Data are shown as the mean ± standard deviation (SD). **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: QRT-PCR was performed using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China).

Techniques: RNA Sequencing, Quantitative RT-PCR, Western Blot, Standard Deviation

MDK promotes cancer metastasis by activating the EMT programme. (A) RT-qPCR validation of MDK overexpression in five cancer cell lines. (B) Transwell assays to assess the alteration of cell invasion and migration abilities by MDK overexpression in five cancer cell lines. (C) Western blotting assays to assess the effect of MDK overexpression on expression of EMT markers. (D) RT-qPCR assays to assess the effect of MDK overexpression on expression of EMT markers. (E) RT-qPCR validation of MDK inhibition by iMDK (100nM, 48h). (F) RT-qPCR and Western blotting assays to assess the effect of iMDK on EMT in five cancer cell lines. (G) Transwell assays to assess the effect of iMDK on cell invasion and migration in five cancer cell lines. Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Journal: Frontiers in Oncology

Article Title: Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins

doi: 10.3389/fonc.2022.885656

Figure Lengend Snippet: MDK promotes cancer metastasis by activating the EMT programme. (A) RT-qPCR validation of MDK overexpression in five cancer cell lines. (B) Transwell assays to assess the alteration of cell invasion and migration abilities by MDK overexpression in five cancer cell lines. (C) Western blotting assays to assess the effect of MDK overexpression on expression of EMT markers. (D) RT-qPCR assays to assess the effect of MDK overexpression on expression of EMT markers. (E) RT-qPCR validation of MDK inhibition by iMDK (100nM, 48h). (F) RT-qPCR and Western blotting assays to assess the effect of iMDK on EMT in five cancer cell lines. (G) Transwell assays to assess the effect of iMDK on cell invasion and migration in five cancer cell lines. Data are shown as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: QRT-PCR was performed using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China).

Techniques: Quantitative RT-PCR, Biomarker Discovery, Over Expression, Migration, Western Blot, Expressing, Inhibition, Standard Deviation

Targeting MDK abrogates IFN-γ-induced tumor metastasis. (A) RT-qPCR validation of MDK suppression by MDK inhibitor in IFN-γ-treated cancer cells. (B) Western blotting and RT-qPCR assays to assess the effect of iMDK on IFN-γ-activated EMT in five cancer cell lines. (C) Transwell assays to examine the effect of iMDK on IFN-γ-driven cell invasion and migration. Data are shown as the mean ± standard deviation (SD). **P < 0.01, ***P < 0.001, ****P < 0.0001.

Journal: Frontiers in Oncology

Article Title: Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins

doi: 10.3389/fonc.2022.885656

Figure Lengend Snippet: Targeting MDK abrogates IFN-γ-induced tumor metastasis. (A) RT-qPCR validation of MDK suppression by MDK inhibitor in IFN-γ-treated cancer cells. (B) Western blotting and RT-qPCR assays to assess the effect of iMDK on IFN-γ-activated EMT in five cancer cell lines. (C) Transwell assays to examine the effect of iMDK on IFN-γ-driven cell invasion and migration. Data are shown as the mean ± standard deviation (SD). **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: QRT-PCR was performed using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China).

Techniques: Quantitative RT-PCR, Biomarker Discovery, Western Blot, Migration, Standard Deviation